HK1018439A1 - 5h-thiazolo (3,2-a) pyrimidine derivatives - Google Patents

5h-thiazolo (3,2-a) pyrimidine derivatives

Info

Publication number
HK1018439A1
HK1018439A1 HK99103032A HK99103032A HK1018439A1 HK 1018439 A1 HK1018439 A1 HK 1018439A1 HK 99103032 A HK99103032 A HK 99103032A HK 99103032 A HK99103032 A HK 99103032A HK 1018439 A1 HK1018439 A1 HK 1018439A1
Authority
HK
Hong Kong
Prior art keywords
thiazolo
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
HK99103032A
Other languages
English (en)
Inventor
Vincent Mutel
Jurgen Wichmann
Geo Adam
Thomas Johannes Woltering
Sabine Kolczewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1018439A1 publication Critical patent/HK1018439A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK99103032A 1997-07-18 1999-07-14 5h-thiazolo (3,2-a) pyrimidine derivatives HK1018439A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112324 1997-07-18

Publications (1)

Publication Number Publication Date
HK1018439A1 true HK1018439A1 (en) 1999-12-24

Family

ID=8227080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99103032A HK1018439A1 (en) 1997-07-18 1999-07-14 5h-thiazolo (3,2-a) pyrimidine derivatives

Country Status (33)

Country Link
US (1) US5958931A (xx)
EP (1) EP0891978B1 (xx)
JP (1) JP3100573B2 (xx)
KR (1) KR100296837B1 (xx)
CN (1) CN1102596C (xx)
AR (1) AR016129A1 (xx)
AT (1) ATE214704T1 (xx)
AU (1) AU738207B2 (xx)
BR (1) BR9802482A (xx)
CA (1) CA2243234C (xx)
CO (1) CO5210884A1 (xx)
CZ (1) CZ288944B6 (xx)
DE (1) DE69804273T2 (xx)
DK (1) DK0891978T3 (xx)
ES (1) ES2172840T3 (xx)
HK (1) HK1018439A1 (xx)
HR (1) HRP980398B1 (xx)
HU (1) HUP9801587A3 (xx)
ID (1) ID21824A (xx)
IL (1) IL125358A (xx)
MA (1) MA26520A1 (xx)
NO (1) NO310512B1 (xx)
NZ (1) NZ330988A (xx)
PE (1) PE97499A1 (xx)
PL (1) PL190218B1 (xx)
PT (1) PT891978E (xx)
RU (1) RU2197493C2 (xx)
SI (1) SI0891978T1 (xx)
TR (1) TR199801367A3 (xx)
TW (1) TW523518B (xx)
UY (1) UY25095A1 (xx)
YU (1) YU29798A (xx)
ZA (1) ZA986250B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
CA2438582C (en) * 2001-01-31 2012-06-26 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
NZ551660A (en) * 2004-06-21 2009-08-28 Hoffmann La Roche Pyrrazolo-pyrimidine derivatives and their use in diseases or conditions where mGluR2 activation plays a role
KR100847160B1 (ko) * 2004-06-21 2008-07-17 에프. 호프만-라 로슈 아게 피라졸로 피리미딘 유도체
EP1851225B1 (en) 2005-02-11 2011-06-15 F. Hoffmann-La Roche AG Pyrazolo-pyrimidine derivatives as mglur2 antagonists
ATE460417T1 (de) 2005-03-23 2010-03-15 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
EP1934214B1 (en) 2005-09-27 2010-04-07 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
RU2492170C9 (ru) * 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102361108B1 (ko) * 2013-10-11 2022-02-10 에프. 호프만-라 로슈 아게 N-메틸-d-아스파르테이트 수용체 활성의 조절자로서의 티아졸로피리미딘온
EP3431106B1 (en) 2014-01-21 2020-12-30 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
KR20200126026A (ko) 2014-01-21 2020-11-05 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CA3054591A1 (en) * 2017-03-31 2018-10-04 Basf Se Pyrimidinium compounds and their mixtures for combating animal pests

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660418A (en) * 1970-03-16 1972-05-02 Sandoz Ag Certain 2 3 5 6-tetrahydroimidazo(2 1-b)thiazoles
EP0524055A1 (fr) * 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
WO1998006724A1 (fr) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique

Also Published As

Publication number Publication date
CO5210884A1 (es) 2002-10-30
BR9802482A (pt) 2000-03-14
NO983244D0 (no) 1998-07-14
CA2243234C (en) 2007-09-18
KR19990013919A (ko) 1999-02-25
ZA986250B (en) 1999-01-22
NO310512B1 (no) 2001-07-16
PE97499A1 (es) 1999-10-12
CA2243234A1 (en) 1999-01-18
KR100296837B1 (ko) 2001-10-26
EP0891978B1 (en) 2002-03-20
TW523518B (en) 2003-03-11
CN1206010A (zh) 1999-01-27
IL125358A (en) 2002-09-12
PL327532A1 (en) 1999-02-01
AU7730298A (en) 1999-01-28
JP3100573B2 (ja) 2000-10-16
ATE214704T1 (de) 2002-04-15
CN1102596C (zh) 2003-03-05
ID21824A (id) 1999-07-29
HRP980398A2 (en) 1999-04-30
NO983244L (no) 1999-01-19
DE69804273D1 (de) 2002-04-25
PL190218B1 (pl) 2005-11-30
SI0891978T1 (en) 2002-06-30
ES2172840T3 (es) 2002-10-01
AR016129A1 (es) 2001-06-20
DK0891978T3 (da) 2002-07-01
IL125358A0 (en) 1999-03-12
RU2197493C2 (ru) 2003-01-27
HUP9801587A3 (en) 2001-09-28
JPH1171380A (ja) 1999-03-16
PT891978E (pt) 2002-07-31
US5958931A (en) 1999-09-28
HU9801587D0 (en) 1998-09-28
DE69804273T2 (de) 2002-10-31
HRP980398B1 (en) 2002-06-30
EP0891978A3 (en) 1999-02-03
CZ223998A3 (cs) 1999-02-17
HUP9801587A2 (hu) 1999-11-29
TR199801367A2 (xx) 1999-02-22
AU738207B2 (en) 2001-09-13
YU29798A (sh) 2001-12-26
EP0891978A2 (en) 1999-01-20
NZ330988A (en) 1999-03-29
MA26520A1 (fr) 2004-12-20
CZ288944B6 (cs) 2001-10-17
TR199801367A3 (tr) 1999-02-22
UY25095A1 (es) 2001-01-31

Similar Documents

Publication Publication Date Title
HK1018439A1 (en) 5h-thiazolo (3,2-a) pyrimidine derivatives
SI1220856T1 (en) Pyrazolo(4,3-d)pyrimidine derivatives
EG23758A (en) Pyrrolo (2,3-d) pyrimidine compounds
SG71077A1 (en) 8-Substituted-1,3, 8-triaza-spiro (4.5)decan-4-on derivatives
IL131521A0 (en) Pyrimidine derivatives
SI0921125T1 (en) 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
HK1026418A1 (en) Novel pyrimidine derivatives and processes for the preparation thereof
ZA985121B (en) 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use.
IL127399A0 (en) 1,3,8-Triaza-spiro (4,5) decan-4-on derivatives
ZA983177B (en) 5,7-Disubstituted-4-aminopyrdo [2,3] pyrimidine compounds
AUPO912997A0 (en) Antiviral agents
HK1025955A1 (en) Novel pyrimidine derivative
ZA982436B (en) Thiazolimine derivatives.
IL136500A0 (en) 1,4-diazacycloheptane derivatives
HU9503012D0 (en) New pyrimidine derivatives
IL131892A0 (en) 6, 7-Disubstituted-4-aminopyrido [2, 3-d] pyrimidine compounds
AU3467197A (en) Tetracyclical derivatives from pyrimidine
AU5678798A (en) Antiviral agents
ZA983175B (en) 5, 6, 7-Trisubstituted-4-aminopyrido (2, 3-d) pyrimidine compounds
ZA981307B (en) 4-aminoethoxyindazole derivatives.
EP0904271A4 (en) 5,6,7,8-tetrahydropyrido [2,3-d] PYRIMIDINE
EP0954316A4 (en) PYRIMIDINE DERIVATIVES
ZA985559B (en) Tetrahydroimidazo Ä2,1-aÜsoquinoline derivatives
AU3500997A (en) 5,6,7,8-tetrahydropyrido{2,3-d}pyrimidine derivatives
AUPO912897A0 (en) Antiviral agents

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060711